Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Teprotumumab Treatment in Patients With Active Thyroid Eye Disease


A Multicenter, Double-masked, Placebo-controlled, Efficacy and Safety Study of an Insulin-like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), in Patients With Active Thyroid Eye Disease




The purpose of this study is to evaluate the safety, tolerability and effectiveness of a fully human antibody compared to placebo in the treatment of patients with active thyroid eye disease.

Study Status: Recruiting


Condition Intervention Phase
Thyroid Associated Ophthalmopathies
Thyroid-Associated Ophthalmopathy
Drug: teprotumumab
Drug: Placebo
Phase 2

Verified by River Vision Development Corporation June, 2013

Sponsored by: River Vision Development Corporation
Information provided by: River Vision Development Corporation identifier: NCT01868997

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Cole Eye Institute at Cleveland Clinic
Cleveland, Ohio 44195
United States

Raymond S Douglas, MD,PhD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site